Causal associations of education, lifestyle behaviors, and cardiometabolic traits

with epigenetic age acceleration: a Mendelian randomization study

Lijie Kong,[1,2]* Chaojie Ye,[1,2]* Yiying Wang,[1,2] Jie Zheng,[3] Shuangyuan Wang,[1,2]

Hong Lin,[1,2] Zhiyun Zhao,[1,2] Mian Li,[1,2] Yu Xu,[1,2] Jieli Lu,[1,2] Yuhong Chen,[1,2] Min

Xu,[1,2] Weiqing Wang,[1,2] Guang Ning,[1,2] Yufang Bi,[1,2] Tiange Wang[1,2]

*Lijie Kong and Chaojie Ye contributed equally as first authors.

Author Affiliations:

[1]Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine

and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of

Medicine, Shanghai, China;

[2]Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory

for Endocrine and Metabolic Diseases of the National Health Commission of the PR

China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of

Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of

Medicine, Shanghai, China;

[3]MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of

Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom.

Correspondence:

Tiange Wang, MD, PhD. Shanghai National Clinical Research Center for Endocrine

and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases,

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rujin 2nd

Road, Shanghai, China. E-mail: wtg@live.cn. Phone number: 86-021-64370045.

Abstract

Background: GrimAge acceleration (GrimAgeAccel) and PhenoAge acceleration (PhenoAgeAccel) are DNA methylation-based markers of accelerated biological aging, standing out in predicting mortality and age-related cardiometabolic morbidities. Whether and to what extent modifiable risk factors are likely to influence GrimAgeAccel and PhenoAgeAccel, if causally established, could shed light on contributors to aging process and intervention targets for preventing age-related diseases and improving healthy longevity.

Methods: We performed two-sample univariable and multivariable Mendelian randomization (MR) to investigate the causal associations of 18 common modifiable socioeconomic, lifestyle, and cardiometabolic factors with GrimAgeAccel and PhenoAgeAccel. We extracted independent genetic variants strongly associated with the 18 modifiable factors from the largest available genome-wide association studies (GWASs) of European ancestry, ensuring minimum sample overlap with the genetic variants for GrimAgeAccel and PhenoAgeAccel. Summary-level data for GrimAgeAccel and PhenoAgeAccel were derived from a GWAS of 34,710 European participants. We used the inverse-variance weighted method as the main analysis, and the weighted median, MR-Egger, and MR pleiotropy residual sum and outlier methods as sensitivity analyses.

Results: Eleven and eight factors were causally associated with GrimAgeAccel and PhenoAgeAccel, respectively. Smoking initiation was the strongest risk factor (β [SE]: 1.299 [0.107] years) for GrimAgeAccel, followed by higher alcohol intake, higher waist circumference, daytime napping, higher body fat percentage, higher BMI, higher C-reactive protein, higher triglycerides, childhood obesity, and type 2 diabetes; whereas education was the strongest protective factor (β [SE] per 1-SD

increase in years of schooling: -1.143 [0.121] years). Higher waist circumference (β

[SE]: 0.850 [0.269] years) and education (β [SE]: -0.718 [0.151] years) were the

leading causal risk and protective factors for PhenoAgeAccel, respectively. Sensitivity

analyses strengthened the robustness of these causal associations, and the

multivariable MR analyses demonstrated independent direct effects of the strongest

risk and protective factors on GrimAgeAccel and PhenoAgeAccel, respectively.

Conclusion: Our findings provide novel quantitative evidence on modifiable causal

risk factors for epigenetic aging, and hints at underlying contributors and intervention

targets to the aging process.

Keywords: Epigenetic age acceleration; Education; Lifestyle behaviors;

Cardiometabolic traits; Mendelian randomization.

Introduction

Aging involves the gradual accumulation of a decline in multiple biological functions over time, leading to increased risks of developing age-related diseases and mortality [1,2]. Although chronological aging is uniform and unchangeable, the rate of biological aging is variable and modifiable depending on individual genetics, environmental exposures, and health-related behaviors [3]. Of several potential types of biological age predictors (e.g., epigenetic clock, leukocyte telomere length, and transcriptomic predictors), the epigenetic clock that composed of DNA methylation at multiple cytosine-phosphate-guanine (CpG) sites is currently the best one, as it correlates well with age and predicts mortality across populations [4]. The epigenetic age acceleration is the difference between chronological age and epigenetic age, and represents accelerated biological aging [5]. The second-generation epigenetic age acceleration indicators, namely GrimAge acceleration (GrimAgeAccel) and PhenoAge acceleration (PhenoAgeAccel), have been evolved to incorporate aging-related traits, and stand out in terms of predicting mortality and age-related cardiometabolic morbidities [6-9].

Limited observational evidence has suggested that certain socioeconomic, lifestyle behaviors, and cardiometabolic traits may be related to GrimAgeAccel and PhenoAgeAccel [6,7,10,11]. Whether and to what extent modifiable risk factors influence GrimAgeAccel and PhenoAgeAccel, if causally established, could shed light on potential contributors to aging process and elucidate promising targets for preventing age-related diseases and improving healthy longevity. [12,13]. Thus far, such causal evidence is scarce.

To fill this knowledge gap, we applied Mendelian randomization (MR) to evaluate the causal associations of 18 common modifiable socioeconomic, lifestyle

and cardiometabolic factors with GrimAgeAccel and PhenoAgeAccel. The MR

method uses genetic variants as instrumental variables (IVs) to infer causality among

correlated traits. Since genetic variants are randomly allocated at conception, the MR

study is less susceptible to confounding and reverse causality than conventional

observational studies [14]. We conducted both univariable and multivariable MR

analyses to discern if modifiable factors have independent direct causal effects on

GrimAgeAccel and PhenoAgeAccel.

Methods

Study design

This MR study design is presented in **Figure 1**. We performed two-sample

univariable and multivariable MR strictly following the STROBE-MR guidelines

(**Supplementary Table 1**) [15]. To obtain unbiased estimates of the causal effects,

the MR analysis should adhere to three fundamental assumptions [16]: first, the IVs

are truly associated with the exposures; second, the IVs are independent of

confounders of the relationship between exposures and outcomes (GrimAgeAccel and

PhenoAgeAccel); third, the IVs influence the outcomes only through the exposures,

but not any direct or indirect pathways. All data used in this MR study are publicly

available. Ethical approval and informed consent had been obtained in all original

studies.

Selection rationale and data sources of genetic instruments

We selected 18 common modifiable factors including educational attainment, lifestyle

behaviors (smoking initiation, alcohol intake, coffee consumption, daytime napping,

sleep duration, and moderate-to vigorous physical activity [MVPA]), and

cardiometabolic traits (body mass index [BMI], waist circumference, body fat

percentage [BF%], childhood obesity, type 2 diabetes, low-density lipoprotein [LDL]

cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides, systolic blood

pressure [SBP], diastolic blood pressure [DBP], and C-reactive protein [CRP]).

Definitions of the 18 modifiable factors are shown in **Supplementary Table 2**.

We extracted genetic variants for each of the modifiable factors from the largest

available genome-wide association studies (GWASs) of European ancestry [17-29],

ensuring minimum sample overlap with the genetic variants for GrimAgeAccel and

PhenoAgeAccel (**Table 1**). We included single nucleotide polymorphisms (SNPs)

robustly associated with the 18 modifiable factors at the genome-wide significance (P

$<5\times10-8$). To select independent genetic variants, a stringent condition (linkage

disequilibrium threshold of r2 <0.01) was set to minimize the influence of linkage

disequilibrium which may bias the results of randomized allele allocation. Where

SNPs for the exposures were not available in the GWAS summary statistics of

GrimAgeAccel or PhenoAgeAccel, we used proxies of SNPs with r2 >0.8 as

substitutes, by using the LDproxy search on the online platform LDlink

(https://ldlink.nci.nih.gov/) [30].

Data source for epigenetic age acceleration

The genetic associations with GrimAgeAccel and PhenoAgeAccel were extracted

from a recent GWAS meta-analysis (summary statistics available at

https://datashare.is.ed.ac.uk/handle/10283/3645), which included 34,710 European

participants from 28 cohorts [31]. GrimAgeAccel and PhenoAgeAccel are two-

generation epigenetic age acceleration indicators, expressing the biological aging rate

in years, of which GrimAgeAccel is more strongly associated with mortality than

PhenoAgeAccel [11]. Detailed definitions of GrimAgeAccel and PhenoAgeAccel and

data preparation in GWAS are shown in **Supplementary Table 2**.

Statistical analyses

In the main analysis, we used the inverse-variance weighted (IVW) method to

determine MR causal estimates (β coefficients with standard errors [SEs]) for

associations of each modifiable factor with GrimAgeAccel and PhenoAgeAccel. The

IVW combined the Wald ratio estimates of every single SNP in the set of IVs into one

causal estimate using the random-effects meta-analysis approach [32]. To evaluate the

robustness of the IVW estimates under different assumptions and to detect possible

pleiotropy, we performed three sensitivity analyses, including the MR weighted

median, the MR Egger, and the MR pleiotropy residual sum and outlier (MR-

PRESSO) methods. The weighted median method selected the median MR estimate

as the causal estimate, and provided a consistent causal estimate if over 50% of the

weight in the analysis was derived from valid IVs [33]. The MR Egger method which

allowed the intercept to be freely estimated as an indicator of pleiotropy was used to

identify and adjust for the potential directional pleiotropic bias, but has limited

precision [34]. The MR-PRESSO method was applied to detect and correct for any

outlier SNP reflecting likely horizontal pleiotropic biases for MR causal estimates

[35]. We evaluated the heterogeneity for the IVW estimates using the Cochran's Q

test [36], and identified the horizontal pleiotropy based on the p-value for the intercept

in the MR-Egger model [34]. A false discovery rate (FDR) method was used to

correct results for multiple testing, and FDR q-values were provided. In this study,

strong causal evidence was defined as an association supported by the main analysis

(FDR q-value <0.05) and at least one sensitivity analysis. Suggestive causal evidence

was defined as a suggest association with P <0.05 and FDR q value ≥0.05 in the main

analysis. Null causal evidence was defined as no statistically significant association

revealed from the main analysis (P ≥0.05).

We further conducted multivariable MR (MVMR) analyses to assess whether the

causal effects of the strongest protective factor and risk factor on GrimAgeAccel and

PhenoAgeAccel were independent of other exposure factors [37]. Taking into account

the effect size and significance of causal associations, we selected exposure factors

with β coefficients >0.5 and P <0.05 in the main analysis as covariates in the

adjustment models.

The two-sample MR analyses were conducted with the R packages

'*TwoSampleMR*' and '*MRPRESSO*' in R software (version 4.0.3). FDR q-values were

estimated using the R package '*fdrtool*'.

Results

MR results for associations between 18 modifiable factors and GrimAgeAccel

Ten out of the 18 risk factors showed strong associations with increased

GrimAgeAccel after FDR adjustment for multiple comparisons (**Table 2**). Smoking

initiation was the strongest risk factor (β [SE]: 1.299 [0.107] years) for

GrimAgeAccel, followed by higher alcohol intake (β [SE] per 1-SD increase: 0.899

[0.361] years), higher waist circumference (β [SE] per 1-SD increase: 0.815 [0.184]

years), daytime napping (β [SE]: 0.805 [0.355] years), higher BF% (β [SE] per 1-SD

increase: 0.748 [0.120] years), higher BMI (β [SE] per 1-SD increase: 0.592 [0.079]

years), higher CRP (β [SE] per 1-SD increase: 0.345 [0.073] years), higher

triglycerides (β [SE] per 1-SD increase: 0.249 [0.091] years), childhood obesity (β

[SE]: 0.200 [0.075] years), and type 2 diabetes (β [SE]: 0.095 [0.041] years; **Figure**

2). By contrast, educational attainment in years of schooling was the only one

protective factor associated with decreased GrimAgeAccel (β [SE] per 1-SD increase:

-1.143 [0.121] years). There was little evidence to support a causal association of

other modifiable factors with GrimAgeAccel.

Associations of the above 11 modifiable factors with GrimAgeAccel were robust

across sensitivity analyses with consistent effect directions and P <0.05 in at least one

sensitivity analysis. The MR-Egger intercept tests indicated potential pleiotropy for

CRP ($P_{intercept}$ <0.05; **Supplementary Table 3**). Cochran's Q-test showed possible

heterogeneity for educational attainment, alcohol intake, BMI, BF%, type 2 diabetes,

LDL cholesterol, HDL cholesterol, and CRP (P_h <0.05; **Supplementary Table 3**).

However, with the exclusion of outlying SNPs, the MR-PRESSO analysis showed

consistent results with the IVW analysis (**Table 2**).

MR results for associations between 18 modifiable factors and PhenoAgeAccel

Eight modifiable factors showed strong associations with PhenoAgeAccel after FDR

adjustment for multiple comparisons (**Table 3**). Higher waist circumference was the

strongest risk factor (β [SE] per 1-SD increase: 0.850 [0.269] years) for

PhenoAgeAccel, followed by higher BF% (β [SE] per 1-SD increase: 0.711 [0.152]

years), higher BMI (β [SE] per 1-SD increase: 0.586 [0.102] years), smoking

initiation (β [SE]: 0.519 [0.142] years), higher CRP (β [SE] per 1-SD increase: 0.349

[0.095] years), childhood obesity (β [SE]: 0.229 [0.095] years), and type 2 diabetes (β

[SE]: 0.125 [0.051] years). Whereas the genetically predicted higher educational

attainment in years of schooling was associated with decreased PhenoAgeAccel (β

[SE] per 1-SD increase: -0.718 [0.151] years; **Figure 3**). Suggestive causality was

identified for the association between genetically predicted higher DBP and increased

PhenoAgeAccel (β [SE] per 1-mmHg increase: 0.049 [0.024] years). No significant

association was observed with PhenoAgeAccel for the other modifiable factors.

Associations for the above eight modifiable factors were robust in sensitivity

analyses with consistent effect directions and P <0.05 in at least one sensitivity

analysis. There was no evidence of pleiotropy for these risk factors except for CRP

($P_{intercept}$ <0.05; **Supplementary Table 4**). Potential heterogeneity was observed for

educational attainment, smoking initiation, BMI, waist circumference, BF%, type 2

diabetes, and CRP (P_h<0.05). One to four outliers were detected in the MR-PRESSO

analyses; however, the associations remained consistent after removal of these

outliers (**Table 3**). For SBP, with excluding the outlying SNP rs62523863, the MR-

PRESSO analysis revealed a potentially positive association between genetically

predicted higher SBP and PhenoAgeAccel (β [SE] per 1-mmHg increase: 0.038

[0.016] years).

MVMR results for associations of the strongest protective and risk factors with

GrimAgeAccel and PhenoAgeAccel

In MVMR analyses, the association between educational attainment (the strongest

protective factor) and GrimAgeAccel was slightly attenuated but remained significant

with adjustment for smoking initiation, BMI, waist circumference, or BF% (**Figure**

4a). Likewise, the significant association between smoking initiation (the strongest

risk factor) and GrimAgeAccel was not substantially changed after adjustment for

BMI, waist circumference, or BF%. All covariates in MVMR analyses were selected

based on their considerable effects on GrimAgeAccel in terms of size (β

coefficients >0.5) and significance (P <0.05 in the main analysis).

Similarly, the associations of education (the strongest protective factor) and

waist circumference (the strongest risk factor) with PhenoAgeAccel remained

significant with adjustment for corresponding covariates (**Figure 4b**).

Discussion

This MR study delineated potential causal relationships between 18 common

modifiable factors and two robust epigenetic age acceleration indicators, the

GrimAgeAccel and PhenoAgeAccel. We identified strong evidence for 11 and eight

factors associated with GrimAgeAccel and PhenoAgeAccel, respectively. Smoking

initiation exhibited the greatest effect on increased GrimAgeAccel (1.299 years),

followed by higher alcohol intake, higher waist circumference, daytime napping,

higher BF%, higher BMI, higher CRP, higher triglycerides, childhood obesity, and

type 2 diabetes; whereas educational attainment showed the greatest effect on

decreased GrimAgeAccel (-1.143 years per 1-SD increase in years of schooling).

Higher waist circumference and educational attainment were the leading causal risk

and protective factors associated with PhenoAgeAccel, respectively; BF%, BMI,

smoking initiation, CRP, childhood obesity, and type 2 diabetes were also associated

with increased PhenoAgeAccel. Multiple sensitivity analyses further strengthened the

robustness of these causal relationships, and the MVMR analyses demonstrated the

independent direct effects of the strongest risk and protective factors on

GrimAgeAccel and PhenoAgeAccel. Suggestive causality was identified for the

association between higher DBP and increased PhenoAgeAccel.

In this study, educational attainment was the major protective factor for both

GrimAgeAccel and PhenoAgeAccel, and this causal effect was largely independent of

other causal factors, such as smoking and adiposity-related traits. Educational

attainment is a strong proxy for socioeconomic status and a more upstream

determinant of health, with broad implications for a person's life-long lifestyle

behaviors and health-promoting resources [38]. A recent study using UK Biobank

data has documented that each 1-year increase in genetically determined educational

attainment was associated with equivalently 4.2 years of age-related increases in

telomere length [39]. Telomere length and epigenetic age acceleration metrics (e.g.,

GrimAgeAccel and PhenoAgeAccel) point towards distinct mechanisms of the aging

process that are marked by telomeres and the DNA methylation-based epigenetic

clocks, both of which are independently associated with chronological age and

mortality risk [40]. Our findings, together with those of the UK Biobank, highlight the

important impact of educational attainment on biological aging rates from two

different aspects of the aging process. Therefore, public health strategies aimed at

reducing educational inequalities and improving educational attainment may slow the

biological aging rate and help reduce age-related health burdens.

    This MR study identified several common lifestyle behaviors, including smoking

initiation, alcohol intake, and daytime napping, causally associated with increased

GrimAgeAccel or PhenoAgeAccel (smoking initiation only), which were consistent

with previous evidence from observational studies [6,7]. Smoking methylation proxy

is a component of the GrimAge clock [7], thus it is not surprising that smoking

initiation exhibited a large effect on increased GrimAgeAccel, and the MVMR

analysis further confirmed that the effect of smoking on GrimAgeAccel was

independent of adiposity-related traits. Similarly, genetically determined smoking has

been associated with shorter telomere length in the UK Biobank [41], and evidence

from the Danish Health Interview Survey suggested that the life expectancy of a

heavy smoker was a little more than seven years shorter than that of a never smoker

[42]. Our study also provided strong MR evidence that genetically predicted higher

alcohol intake was associated with increased GrimAgeAccel. A study composed of the

Hannum cohort and Family and Community Health Studies cohort found that the

relationship between alcohol use and the first-generation epigenetic clocks seemed to

be nonlinear [42]. However, given the dose-dependent relationship of alcohol intake

with all-cause mortality and cancers [43], our findings suggest that reducing alcohol

intake is necessary to decrease GrimAgeAccel and retard the overall health loss.

Previous observational studies also reported positive or negative correlations of other

lifestyle behaviors such as MVPA, coffee, and sleep duration with GrimAgeAccel,

PhenoAgeAccel, or mortality [11,44,45]. Nevertheless, in this study, there was little

evidence supporting these associations were causal. The discrepancy between our

findings and previous observations may result from bias from confounding or reverse

causation or non-linear association patterns, as in the case of sleep duration and

mortality [46], therefore, our null findings should be cautiously interpreted.

Interestingly, of all cardiometabolic traits (i.e., adiposity traits, type 2 diabetes,

triglycerides, and CRP) which causally increased GrimAgeAccel or PhenoAgeAccel,

adiposity traits were the most dominant traits. Emerging observational studies have

pronounced the positive associations of BMI with GrimAgeAccel and

PhenoAgeAccel [11], and a meta-analysis of 87 observational studies showed each 5-

kg/m^2 higher BMI corresponded to about 1 year of age-related decrease in telomere

length [46]. Our study further provided strong evidence for causal associations of

various adiposity phenotypes, including BMI, waist circumference, BF%, and

childhood obesity, with increased GrimAgeAccel and PhenoAgeAccel. In this study,

type 2 diabetes, triglycerides, and CRP showed strong but modest effects (β

coefficients ≤0.5) on GrimAgeAccel or PhenoAgeAccel, which was consistent with

the findings of the UK Biobank study on telomere length [39].

Our study identifies education, lifestyle behaviors, and cardiometabolic traits

associated with accelerating or decelerating epigenetic aging, which brings us one

step closer to understanding the potential contributors to the aging process and

provides promising intervention targets for healthy aging. Given the enormous burden

induced by age-related morbidity and mortality, strategies to reduce educational

inequalities, promote healthy lifestyles primarily through reducing smoking, alcohol

intake, and daytime napping, and improve cardiometabolic traits, specifically

adiposity, type 2 diabetes, triglycerides, and CRP, to slow biological aging rate are

imminent.

To our knowledge, this MR study for the first time showed causal associations of

comprehensive modifiable risk factors with GrimAgeAccel and PhenoAgeAccel, the

robust second-generation epigenetic age acceleration indicators. We included

independent and genome-wide significant SNPs as instruments for each of the

modifiable factors to ensure the first MR assumption was fulfilled. Moreover, we

applied strict criteria strengthened by the FDR-corrected significance and the cross-

validations by main and sensitivity analyses to draw robust causal conclusions.

Several limitations merited consideration. First, we found potential pleiotropy

from the MR-Egger intercept test for CRP. However, we conducted MR-PRESSO

analysis, and the association remained consistent after removal of outlying SNPs.

Second, we could not rule out the possibility that the associations of certain

modifiable risk factors such as alcohol intake and sleep duration with GrimAgeAccel

or PhenoAgeAccel may be non-linear. Future studies with individual-level data are

warranted to confirm the linear or non-linear relationships. Third, to ensure the

consistency of genetic background, this MR study was performed only in European-ancestry participants, thus the generalization of our results to other ethnic groups should be cautious.

Conclusions

This MR study provided novel quantitative evidence on the modifiable causal risk profile of 11 socioeconomic, lifestyle, and cardiometabolic factors for epigenetic age acceleration. Our findings shed light on the underlying contributors to the biological aging process and point toward potential intervention targets to slow the biological aging rate and promote healthy longevity.

347   **List of abbreviations**

BF%	Body fat percentage
BMI	Body mass index
CI	Confidence interval
CpG	Cytosine-phosphate-guanine
CRP	C-reactive protein
DBP	Diastolic blood pressure
FDR	False discovery rate
GrimAgeAccel	GrimAge acceleration
GWAS	Genome-wide association study
HDL	High-density lipoprotein
IV	Instrumental variable
IVW	Inverse variance weighted
LDL	Low-density lipoprotein
MVPA	Moderate-to vigorous physical activity
MR	Mendelian randomization
MVMR	Multivariable Mendelian randomization
PhenoAgeAccel	PhenoAge acceleration
PRESSO	Pleiotropy residual sum and outlier
SBP	Systolic blood pressure
SD	Standard deviation
SE	Standard errors
SNP	Single nucleotide polymorphism
WM	Weighted median

Conflict-of-interest statement

The authors declare that they have no competing interests

Ethics approval and consent to participate

This study is based on publicly available summarized data. Ethical approval and informed consent had been obtained in all original studies.

Availability of data and materials

The genetic association data of the 18 modifiable factors are available in Table 1. The GWAS summary statistics for GrimAgeAccel and PhenoAgeAccel are available at https://datashare.is.ed.ac.uk/handle/10283/3645. The analytical script of the MR analyses conducted in this study is available via the GitHub repository of the "TwoSampleMR" R package (https://github.com/MRCIEU/TwoSampleMR/).

Funding

This work was supported by the grants from the National Natural Science Foundation of China (82022011, 81970706, 81730023, 82088102, 81970728, 81941017), the Chinese Academy of Medical Sciences (2018PT32017, 2019PT330006), the "Shanghai Municipal Education Commission–Gaofeng Clinical Medicine Grant Support" from Shanghai Jiao Tong University School of Medicine (20171901 Round 2), the Shanghai Shenkang Hospital Development Center (SHDC12019101, SHDC2020CR1001A, SHDC2020CR3064B), the Shanghai Jiao Tong University School of Medicine (DLY201801), and the Ruijin Hospital (2018CR002).

Authors' contributions

LK and TW contributed to the conception and design of the study. LK and CY

contributed to statistical analysis. LK contributed to drafting of the manuscript. TW

guaranteed this work and take responsibility for the integrity of the data. All authors

contributed to acquisition or interpretation of data, critical revision of the manuscript

for important intellectual content, and final approval of the version to be published.

Acknowledgements

We gratefully acknowledge the investigators and participants of all genome-wide

association studies from which we used data.

References

1. Niccoli T, Partridge L. Ageing as a risk factor for disease. *Curr Biol.* 2012;**22(17):**R741-R52.

2. Schumacher B, Pothof J, Vijg J, Hoeijmakers JHJ. The central role of DNA damage in the ageing process. *Nature.* 2021;**592(7856):**695-703.

3. Warner HR. Current status of efforts to measure and modulate the biological rate of aging. *J Gerontol A Biol Sci Med Sci.* 2004;**59(7):**692-6.

4. Jylhävä J, Pedersen NL, Hägg S. Biological Age Predictors. *EBioMedicine.* 2017;**21:**29-36.

5. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nat Rev Genet.* 2018;**19(6):**371-84.

6. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY).* 2018;**10(4):**573-91.

7. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging (Albany NY).* 2019;**11(2):**303-27.

8. Wang C, Ni W, Yao Y, et al. DNA methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: The NAS, and KORA F4. *EBioMedicine.* 2021;**63:**103151.

9. Li A, Koch Z, Ideker T. Epigenetic aging: Biological age prediction and informing a mechanistic theory of aging [published online ahead of print, 2022 Jun 20]. J *Intern*

Med.

10. Quach A, Levine ME, Tanaka T, Lu AT, Chen BH, Ferrucci L, et al. Epigenetic

clock analysis of diet, exercise, education, and lifestyle factors. *Aging (Albany NY)*.

2017;**9(2):**419-46.

11. Oblak L, van der Zaag J, Higgins-Chen AT, Levine ME, Boks MP. A systematic

review of biological, social and environmental factors associated with epigenetic

clock acceleration. *Ageing Res Rev.* 2021;**69:**101348.

12. Sierra F, Caspi A, Fortinsky RH, Haynes L, Lithgow GJ, Moffitt TE, et al. Moving

geroscience from the bench to clinical care and health policy. *J Am Geriatr Soc.*

2021;**69(9):**2455-63.

13. Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From

discoveries in ageing research to therapeutics for healthy ageing. *Nature.*

2019;**571(7764):**183-92.

14. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation

studies: a guide, glossary, and checklist for clinicians. *BMJ.* 2018;**362:**k601.

15. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA,

VanderWeele TJ, et al. Strengthening the reporting of observational studies in

epidemiology using mendelian randomisation (STROBE-MR): explanation and

elaboration. *BMJ.* 2021;**375:**n2233.

16. Zheng J, Baird D, Borges M-C, Bowden J, Hemani G, Haycock P, et al. Recent

Developments in Mendelian Randomization Studies. *Curr Epidemiol Rep*.

2017;**4(4):**330-45.

17. Lee JJ, Wedow R, Okbay A, et al. Gene discovery and polygenic prediction from a

genome-wide association study of educational attainment in 1.1 million individuals.

Nat Genet. 2018;**50(8):**1112-1121.

18. Liu M, Jiang Y, Wedow R, et al. Association studies of up to 1.2 million

individuals yield new insights into the genetic etiology of tobacco and alcohol use.

Nat Genet. 2019;**51(2):**237-244.

19. Zhong VW, Kuang A, Danning RD, et al. A genome-wide association study of

bitter and sweet beverage consumption [published correction appears in Hum Mol

Genet. 2019 May 02;:]. *Hum Mol Genet*. 2019;**28(14):**2449-2457.

20. Dashti HS, Daghlas I, Lane JM, et al. Genetic determinants of daytime napping

and effects on cardiometabolic health. *Nat Commun*. 2021;**12(1):**900.

21. Dashti HS, Jones SE, Wood AR, et al. Genome-wide association study identifies

genetic loci for self-reported habitual sleep duration supported by accelerometer-

derived estimates. *Nat Commun*. 2019;**10(1):**1100.

22. Klimentidis YC, Raichlen DA, Bea J, et al. Genome-wide association study of

habitual physical activity in over 377,000 UK Biobank participants identifies multiple

variants including CADM2 and APOE. *Int J Obes (Lond)*. 2018;**42(6):**1161-1176.

23. Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genome-wide

association studies for height and body mass index in ~700000 individuals of

European ancestry. *Hum Mol Genet*. 2018;**27(20):**3641-3649.

24. Shungin D, Winkler TW, Croteau-Chonka DC, et al. New genetic loci link adipose

and insulin biology to body fat distribution. *Nature*. 2015;**518(7538):**187-196.

25. Bradfield JP, Taal HR, Timpson NJ, et al. A genome-wide association meta-

analysis identifies new childhood obesity loci. *Nat Genet*. 2012;**44(5):**526-531.

26. Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to

single-variant resolution using high-density imputation and islet-specific epigenome

maps. *Nat Genet*. 2018;**50(11):**1505-1513.

27. Klarin D, Damrauer SM, Cho K, et al. Genetics of blood lipids among ~300,000

multi-ethnic participants of the Million Veteran Program. *Nat Genet*.

2018;**50(11):**1514-1523.

28. Evangelou E, Warren HR, Mosen-Ansorena D, et al. Genetic analysis of over 1

million people identifies 535 new loci associated with blood pressure traits [published

correction appears in Nat Genet. 2018 Dec;50(12):1755]. *Nat Genet*.

2018;**50(10):**1412-1425.

29. Han X, Ong JS, An J, Hewitt AW, Gharahkhani P, MacGregor S. Using Mendelian

randomization to evaluate the causal relationship between serum C-reactive protein

levels and age-related macular degeneration. *Eur J Epidemiol*. 2020;**35(2):**139-146.

30. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring

population-specific haplotype structure and linking correlated alleles of possible

functional variants. *Bioinformatics*. 2015;**31(21):**3555-7.

31. McCartney DL, Min JL, Richmond RC, Lu AT, Sobczyk MK, Davies G, et al.

Genome-wide association studies identify 137 genetic loci for DNA methylation

biomarkers of aging. *Genome Biol*. 2021;**22(1):**194.

32. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian

randomization: using genes as instruments for making causal inferences in

epidemiology. *Stat Med*. 2008;**27(8):**1133-1163.

33. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in

Mendelian Randomization with Some Invalid Instruments Using a Weighted Median

Estimator. *Genet Epidemiol*. 2016;**40(4):**304-314.

34. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for

Robust Causal Inference from Mendelian Randomization Analyses with Multiple

Genetic Variants. *Epidemiology (Cambridge, Mass)*. 2017;**28(1):**30-42.

35. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal

pleiotropy in causal relationships inferred from Mendelian randomization between

complex traits and diseases. *Nat Genet.* 2018;**50(5):**693-8.

36. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A

framework for the investigation of pleiotropy in two-sample summary data Mendelian

randomization. *Stat Med.* 2017;**36(11):**1783-802.

37. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of

pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol*.

2015;**181(4):**251-260.

38. Figgins E, Pieruccini-Faria F, Speechley M, Montero-Odasso M. Potentially

modifiable risk factors for slow gait in community-dwelling older adults: A systematic

review. *Ageing Res Rev*. 2021;**66:**101253.

39. Bountziouka V, Musicha C, Allara E, et al. Modifiable traits, healthy behaviours,

and leukocyte telomere length: a population-based study in UK Biobank. *Lancet*

Healthy Longev. 2022;**3(5):**e321-e331.

40. Marioni RE, Harris SE, Shah S, et al. The epigenetic clock and telomere length

are independently associated with chronological age and mortality [published

correction appears in Int J Epidemiol. 2018 Feb 1;47(1):356]. *Int J Epidemiol*.

2018;**45(2):**424-432.

41. Brønnum-Hansen H, Juel K. Abstention from smoking extends life and

compresses morbidity: a population based study of health expectancy among smokers

and never smokers in Denmark. *Tob Control*. 2001;**10(3):**273-278.

42. Beach SR, Dogan MV, Lei MK, et al. Methylomic Aging as a Window onto the

Influence of Lifestyle: Tobacco and Alcohol Use Alter the Rate of Biological Aging. *J*

Am Geriatr Soc. 2015;**63(12):**2519-2525.

43. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease

attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a

systematic analysis for the Global Burden of Disease Study 2016 [published

correction appears in Lancet Psychiatry. 2019 Jan;6(1):e2]. *Lancet Psychiatry*.

2018;**5(12):**987-1012.

44. Loftfield E, Cornelis MC, Caporaso N, Yu K, Sinha R, Freedman N. Association

of Coffee Drinking With Mortality by Genetic Variation in Caffeine Metabolism:

Findings From the UK Biobank. *JAMA Intern Med*. 2018;**178(8):**1086-1097.

45. Wang C, Bangdiwala SI, Rangarajan S, et al. Association of estimated sleep

duration and naps with mortality and cardiovascular events: a study of 116 632 people

from 21 countries. *Eur Heart J*. 2019;**40(20):**1620-1629.

46. Gielen M, Hageman GJ, Antoniou EE, et al. Body mass index is negatively

associated with telomere length: a collaborative cross-sectional meta-analysis of 87

observational studies. *Am J Clin Nutr.* 2018;**108(3)**:453-475.

Table 1. Data sources of IVs for the 18 modifiable factors used in the MR study

Modifiable factor	PMID/ GWAS ID	Sample size	Ancestry	No. of SNPs[a]	Unit	P threshold[b]
Socioeconomic factor						
Educational attainment[17]	30038396	1131881	European	751	1-SD increase in years of schooling	$P < 5 \times 10^{-8}$
Lifestyle behavior						
Smoking initiation[18]	30643251	557337 cases and 674754 controls	European	299	log-odds (ever smoked regularly compared to never smoked)	$P < 5 \times 10^{-8}$
Alcohol intake[18]	30643251	941280	European	80	1-SD increase in log-transformed alcoholic drinks/week	$P < 5 \times 10^{-8}$
Coffee consumption[19]	31046077	375833	European	12	1% change	$P < 5 \times 10^{-8}$
Sleep						
Daytime napping[20]	33568662	452633	European	115	1 unit increase in napping category (responses "never, sometimes or usually napping" were treated as continuous variable)	$P < 5 \times 10^{-8}$
Sleep duration[21]	30846698	446118	European	77	1 hour/day	$P < 5 \times 10^{-8}$
MVPA[22]	29899525	377234	European	6	1-SD increase in MET-minutes/week of MVPA	$P < 5 \times 10^{-9}$
Cardiometabolic trait						
Adiposity						
BMI[23]	30124842	681275	European	941	1-SD increase in body mass index	$P < 5 \times 10^{-8}$

Waist circumference[24]	25673412	224459	European	44	1-SD increase in waist circumference	$P < 5 \times 10^{-8}$
BF%	ukb-b-8909	454633	European	641	1-SD increase in body fat percentage	$P < 5 \times 10^{-8}$
Childhood obesity[25]	22484627	5530 cases and 8318 controls	European	5	log-odds	$P < 5 \times 10^{-8}$
Type 2 diabetes[26]	30297969	71124 cases and 824006 controls	European	232	log-odds	$P < 5 \times 10^{-8}$
Lipids[27]						
LDL cholesterol	30275531	> 600000	mix	145	1-SD increase in LDL cholesterol	$P < 5 \times 10^{-8}$
HDL cholesterol	30275531	> 600000	mix	222	1-SD increase in HDL cholesterol	$P < 5 \times 10^{-8}$
Triglycerides	30275531	> 600000	mix	172	1-SD increase in triglycerides	$P < 5 \times 10^{-8}$
Blood pressure[28]						
SBP	30224653	>1 million	European	222	1 mmHg	$P < 5 \times 10^{-8}$
DBP	30224653	>1 million	European	264	1 mmHg	$P < 5 \times 10^{-8}$
CRP[29]	31900758	418642	European	299	1-SD increase in serum CRP levels	$P < 5 \times 10^{-8}$

[a]SNPs used in the present MR analysis.

[b]P threshold represents genome-wide significance threshold of genetic instruments.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; GWAS=genome-wide association study; HDL=high-density lipoprotein; IVs=instrumental variables; LDL=low-density lipoprotein; MVPA=moderate-to vigorous physical activity; MR=Mendelian randomization; No=number; SBP=systolic blood pressure; SD=standard deviation; SNP=single nucleotide polymorphism.

Table 2. MR results of the associations between 18 modifiable factors and GrimAgeAccel

| | | Main analysis | | | | | | Sensitivity analyses | | | | | | |
| | | IVW | | | Weighted median | | | MR-Egger | | | MR-PRESSO | | | |
Modifiable factor	No. of SNP	β (SE)	P value	q value	β (SE)	P value	q value	β (SE)	P value	q value	No. of outlier	β (SE)	P value	q value
Socioeconomic factor														
Educational attainment	751	**-1.143 (0.121)**	**3.31E-21**	2.98E-20	**-1.129 (0.172)**	**5.47E-11**	4.92E-10	-0.829 (0.452)	0.067	0.277	4	**-1.116 (0.116)**	**6.54E-21**	5.89E-20
Lifestyle behavior														
Smoking initiation	299	**1.299 (0.107)**	**4.90E-34**	8.82E-33	**1.257 (0.157)**	**1.42E-15**	2.56E-14	**1.321 (0.446)**	**0.003**	0.027	0	**1.276 (0.103)**	**7.63E-29**	1.37E-27
Alcohol intake	80	**0.899 (0.361)**	**0.013**	0.026	0.380 (0.567)	0.502	0.602	0.481 (0.738)	0.516	0.771	0	**0.967 (0.357)**	**0.008**	0.018
Coffee consumption	12	0.003 (0.005)	0.589	0.624	-0.003 (0.006)	0.615	0.692	-0.008 (0.010)	0.464	0.771	0	0.003 (0.005)	0.600	0.635
Sleep														
Daytime napping	115	**0.805 (0.355)**	**0.023**	0.038	0.524 (0.514)	0.308	0.449	0.411 (1.235)	0.740	0.833	0	**0.813 (0.346)**	**0.020**	0.033
Sleep duration	77	-0.301 (0.266)	0.257	0.356	-0.403 (0.400)	0.313	0.449	-0.077 (1.017)	0.940	0.940	0	-0.275 (0.261)	0.294	0.378
MVPA	6	-0.186 (0.903)	0.837	0.837	-0.036 (1.198)	0.976	0.976	-9.279 (5.557)	0.170	0.510	0	-0.186 (0.763)	0.817	0.817
Cardiometabolic trait														
Adiposity														
BMI	941	**0.592 (0.079)**	**9.16E-14**	5.50E-13	**0.490 (0.124)**	**7.92E-05**	3.56E-04	**0.790 (0.231)**	**0.001**	0.018	2	**0.595 (0.078)**	**6.30E-14**	3.78E-13
Waist circumference	44	**0.815 (0.184)**	**9.26E-06**	2.78E-05	**0.776 (0.272)**	**0.004**	0.014	0.913 (0.504)	0.077	0.277	0	**0.815 (0.184)**	**6.31E-05**	1.89E-04
BF%	641	**0.748 (0.120)**	**4.12E-10**	1.85E-09	**0.740 (0.182)**	**4.87E-05**	2.92E-04	**0.843 (0.400)**	**0.036**	0.216	3	**0.796 (0.115)**	**1.19E-11**	5.36E-11
Childhood obesity	5	**0.200 (0.075)**	**0.007**	0.016	0.142 (0.098)	0.146	0.292	0.789 (0.554)	0.249	0.560	0	**0.204 (0.057)**	**0.016**	0.029
Type 2 diabetes	232	**0.095 (0.041)**	**0.020**	0.036	0.084 (0.071)	0.236	0.425	0.043 (0.092)	0.644	0.773	0	**0.100 (0.040)**	**0.013**	0.026
Lipids														
LDL cholesterol	145	-0.094 (0.096)	0.327	0.392	-0.064 (0.163)	0.695	0.736	0.016 (0.142)	0.908	0.940	1	-0.069 (0.094)	0.463	0.542
HDL cholesterol	223	-0.181 (0.095)	0.056	0.084	-0.267 (0.138)	0.053	0.136	-0.078 (0.162)	0.632	0.773	2	-0.175 (0.090)	0.054	0.081
Triglycerides	173	**0.249 (0.091)**	**0.006**	0.015	0.239 (0.144)	0.096	0.216	0.152 (0.152)	0.319	0.638	0	**0.254 (0.091)**	**0.006**	0.015
Blood pressure														
SBP	222	0.013 (0.012)	0.279	0.359	0.015 (0.018)	0.421	0.541	0.029 (0.049)	0.557	0.771	0	0.013 (0.012)	0.282	0.378
DBP	264	0.011 (0.019)	0.565	0.624	0.027 (0.027)	0.324	0.449	0.083 (0.066)	0.213	0.548	0	0.013 (0.018)	0.482	0.542
CRP	299	**0.345 (0.073)**	**2.31E-06**	8.32E-06	**0.245 (0.107)**	**0.022**	0.066	0.060 (0.100)	0.553	0.771	1	**0.348 (0.071)**	**1.64E-06**	5.90E-06

GrimAgeAccel represents epigenetic-age acceleration obtained using the GrimAge clock. The q value represents the false discovery rate (FDR)-adjusted *P* value. β represents the associations with GrimAgeAccel of respectively: 1-SD increase in years of educational attainment; Ever smoked regularly compared to never smoked; 1-SD increase in log-transformed alcoholic drinks per week; 1%-change in coffee consumption; 1-unit increase in napping category (never, sometimes, usually); 1-hour/day increase in sleep duration; 1-SD increase in MET-minutes/week of MVPA; 1-SD increase in BMI; 1-SD increase in waist circumference; 1-SD increase in BF%; 1-unit increase in log-transformed odds of childhood obesity; 1-unit increase in log-transformed odds of type 2 diabetes; 1-SD increase in LDL cholesterol; 1-SD increase in HDL cholesterol; 1-SD increase in triglycerides; 1-mmHg increase in SBP; 1-mmHg increase in DBP; 1-SD increase in serum CRP levels.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; HDL=high-density lipoprotein; IVW=Inverse variance weighted; LDL=low-density lipoprotein; MVPA=moderate-to vigorous physical activity; MR=Mendelian randomization; MR-PRESSO=Mendelian randomization pleiotropy residual sum and outlier; No=number; SBP=systolic blood pressure; SD=standard deviation; SNP=single nucleotide polymorphism.

Table 3. MR results of the associations between 18 modifiable factors and PhenoAgeAccel

		Main analysis			Sensitivity analyses									
		IVW			Weighted median			MR-Egger			MR-PRESSO			
Modifiable factor	No. of SNP	β (SE)	P value	q value	β (SE)	P value	q value	β (SE)	P value	q value	No. of outlier	β (SE)	P value	q value
Socioeconomic factor														
Educational attainment	751	**-0.718 (0.151)**	**1.83E-06**	1.65E-05	**-0.633 (0.225)**	**0.005**	0.030	-0.361 (0.565)	0.523	0.930	3	**-0.689 (0.145)**	**2.52E-06**	2.27E-05
Lifestyle behavior														
Smoking initiation	299	**0.519 (0.142)**	**2.43E-04**	0.001	**0.404 (0.205)**	**0.049**	0.221	**1.222 (0.589)**	**0.039**	0.240	1	**0.545 (0.135)**	**7.20E-05**	3.24E-04
Alcohol intake	80	0.669 (0.441)	0.130	0.213	1.134 (0.656)	0.084	0.252	1.693 (0.923)	0.070	0.252	0	0.737 (0.432)	0.092	0.151
Coffee consumption	12	0.004 (0.008)	0.600	0.735	0.002 (0.007)	0.773	0.991	-0.003 (0.015)	0.861	0.930	0	0.004 (0.008)	0.610	0.705
Sleep														
Daytime napping	115	0.115 (0.500)	0.818	0.818	0.014 (0.665)	0.984	0.991	0.152 (1.742)	0.931	0.931	0	0.083 (0.488)	0.866	0.866
Sleep duration	77	-0.472 (0.357)	0.187	0.281	-0.526 (0.462)	0.255	0.417	**2.771 (1.324)**	**0.040**	0.240	0	-0.319 (0.357)	0.375	0.519
MVPA	6	0.368 (1.138)	0.747	0.791	0.262 (1.347)	0.846	0.991	-2.565 (6.947)	0.731	0.930	0	0.368 (0.649)	0.596	0.705
Cardiometabolic trait														
Adiposity														
BMI	941	**0.586 (0.102)**	**1.08E-08**	1.94E-07	**0.680 (0.170)**	**6.33E-05**	0.001	0.510 (0.298)	0.087	0.261	4	**0.605 (0.099)**	**1.53E-09**	2.75E-08
Waist circumference	44	**0.850 (0.269)**	**0.002**	0.006	0.632 (0.339)	0.062	0.223	0.739 (0.740)	0.324	0.704	1	**0.771 (0.249)**	**0.003**	0.009
BF%	641	**0.711 (0.152)**	**2.88E-06**	1.73E-05	**0.734 (0.227)**	**0.001**	0.009	**1.666 (0.509)**	**0.001**	0.018	4	**0.664 (0.145)**	**5.75E-06**	3.45E-05
Childhood obesity	5	**0.229 (0.095)**	**0.016**	0.036	0.154 (0.123)	0.211	0.380	0.140 (0.724)	0.859	0.930	0	**0.223 (0.071)**	**0.025**	0.050
Type 2 diabetes	232	**0.125 (0.051)**	**0.014**	0.036	0.102 (0.080)	0.205	0.380	0.056 (0.116)	0.628	0.930	0	**0.120 (0.049)**	**0.016**	0.036
Lipids														
LDL cholesterol	145	0.055 (0.123)	0.653	0.735	-0.002 (0.174)	0.991	0.991	0.169 (0.181)	0.352	0.704	1	0.059 (0.123)	0.633	0.705
HDL cholesterol	223	-0.127 (0.109)	0.243	0.336	0.068 (0.166)	0.684	0.947	0.103 (0.187)	0.583	0.930	0	-0.121 (0.109)	0.267	0.401
Triglycerides	173	-0.058 (0.121)	0.635	0.735	0.009 (0.196)	0.964	0.991	-0.202 (0.203)	0.320	0.704	0	-0.052 (0.121)	0.666	0.705
Blood pressure														
SBP	222	0.032 (0.016)	0.053	0.095	0.033 (0.023)	0.149	0.338	-0.013 (0.065)	0.840	0.930	1	**0.038 (0.016)**	**0.015**	0.036
DBP	264	**0.049 (0.024)**	**0.037**	0.074	0.048 (0.034)	0.150	0.338	0.161 (0.084)	0.055	0.248	0	0.042 (0.023)	0.069	0.124
CRP	298	**0.349 (0.095)**	**2.49E-04**	0.001	0.061 (0.150)	0.684	0.947	0.020 (0.132)	0.878	0.930	1	**0.362 (0.093)**	**1.16E-04**	4.18E-04

PhenoAgeAccel represents epigenetic-age acceleration obtained using the PhenoAge clock; The q value represents the false discovery rate (FDR)-adjusted *P* value. β represents the associations with PhenoAgeAccel of respectively: 1-SD increase in years of educational attainment; Ever smoked regularly compared to never smoked; 1-SD increase in log-transformed alcoholic drinks per week; 1%-change in coffee consumption; 1-unit increase in napping category (never, sometimes, usually); 1-hour/day increase in sleep duration; 1-SD increase in MET-minutes/week of MVPA; 1-SD increase in BMI; 1-SD increase in waist circumference; 1-SD increase in BF%; 1-unit increase in log-transformed odds of childhood obesity; 1-unit increase in log-transformed odds of type 2 diabetes; 1-SD increase in LDL cholesterol; 1-SD increase in HDL cholesterol; 1-SD increase in triglycerides; 1-mmHg increase in SBP; 1-mmHg increase in DBP; 1-SD increase in serum CRP levels.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; HDL=high-density lipoprotein; IVW=Inverse variance weighted; LDL=low-density lipoprotein; MVPA=moderate-to vigorous physical activity; MR=Mendelian randomization; MR-PRESSO=Mendelian randomization pleiotropy residual sum and outlier; No=number; SBP=systolic blood pressure; SD=standard deviation; SNP=single nucleotide polymorphism

Figure 1. Study design and assumptions of the MR analysis

Assumption 1 indicates that the genetic variants proposed as instrumental variables should be robustly associated with the exposures; assumption 2 indicates that the used instrumental variables should not be associated with potential confounders of the relationship between exposures and outcomes; and assumption 3 indicates that the selected instrumental variables should influence the outcomes only through the exposures, not via alternative pathways.

Abbreviations: GrimAgeAccel=epigenetic-age acceleration obtained using the GrimAge clock; HDL=high-density lipoprotein; LDL=low-density lipoprotein; MR=mendelian randomization; PhenoAgeAccel=epigenetic-age acceleration obtained using the PhenoAge clock; PRESSO=pleiotropy residual sum and outlier.

Figure 2. Overview of the findings on associations between 18 modifiable factors and GrimAgeAccel

The IVW method was used for the main analysis. Sensitivity analyses included the MR-PRESSO, the MR-WM, and the MR-Egger methods. All results described here can be found in Table 2.

GrimAgeAccel represents epigenetic-age acceleration obtained using the GrimAge clock. β represents the association of each modifiable factor on GrimAgeAccel. Red box indicates a strong association with p value <0.05 and FDR q value <0.05. Blue box indicates a suggestive association with p value <0.05 and FDR q value ≥0.05. Grey box indicates null association with p value ≥0.05.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; HDL=high-density lipoprotein; IVW=inverse-variance weighted; LDL=low-density lipoprotein; MR=mendelian randomization; MVPA=moderate to vigorous physical activity; PRESSO=pleiotropy residual sum and outlier; SBP=systolic blood pressure; SD=standard deviation; WM=weighted median.

Figure 3. Overview of the findings on associations between 18 modifiable factors and PhenoAgeAccel

The IVW method was used for the main analysis. Sensitivity analyses included the MR-PRESSO, the MR-WM, and the MR-Egger methods. All results described here can be found in Table 3.

PhenoAgeAccel represents epigenetic-age acceleration obtained using the PhenoAge clock; β represents the associations of each modifiable factor on PhenoAgeAccel. Red box indicates a strong association with p value <0.05 and FDR q value <0.05. Blue box indicates a suggestive association with p value <0.05 and FDR q value ≥0.05. Grey box indicates null association with p value ≥0.05.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; HDL=high-density lipoprotein; IVW=inverse-variance weighted; LDL=low-density lipoprotein; MR=mendelian randomization; MVPA=moderate to vigorous physical activity; PRESSO=pleiotropy residual sum and outlier; SBP=systolic blood pressure; SD=standard deviation; WM=weighted median.

Figure 4. Univariable and multivariable MR assessing the effects of the strongest protective factor and risk factor on GrimAgeAccel and PhenoAgeAccel

Causal estimates are β (95% CI) in years.

GrimAgeAccel represents epigenetic-age acceleration obtained using the GrimAge clock; PhenoAgeAccel represents epigenetic-age acceleration obtained using the PhenoAge clock.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CI=confidence intervals; MR=mendelian randomization.

a

Modifiable factor	β (95% CI)
Education	
Unadjusted	-1.138 (-1.405 to -0.871)
Adjusted for smoking initiation	-0.752 (-1.052 to -0.452)
Adjusted for alcohol intake	-1.141 (-1.410 to -0.872)
Adjusted for daytime napping	-1.152 (-1.422 to -0.882)
Adjusted for BMI	-1.012 (-1.302 to -0.722)
Adjusted for waist circumference	-1.050 (-1.366 to -0.734)
Adjusted for BF%	-0.947 (-1.227 to -0.667)
Smoking initiation	
Unadjusted	1.154 (0.858 to 1.450)
Adjusted for BMI	0.850 (0.605 to 1.095)
Adjusted for waist circumference	1.103 (0.787 to 1.419)
Adjusted for BF%	1.017 (0.754 to 1.280)

-1.5 -1.0 -0.5 0.0 0.5 1.0 1.5
←deceleration   acceleration→

b

Modifiable factor	β (95% CI)
Education	
Unadjusted	-0.902 (-1.233 to -0.571)
Adjusted for smoking initiation	-0.691 (-1.069 to -0.313)
Adjusted for BMI	-0.807 (-1.191 to -0.423)
Adjusted for waist circumference	-0.794 (-1.186 to -0.402)
Adjusted for BF%	-0.638 (-0.993 to -0.283)
Waist circumference	
Unadjusted	0.948 (0.376 to 1.520)
Adjusted for smoking initiation	0.768 (0.255 to 1.281)

-1.5 -1.0 -0.5 0.0 0.5 1.0 1.5
←deceleration   acceleration→